LEP and obesity due to melanocortin 4 receptor deficiency: FDA approval has been given, however, to metreleptin, an analog of leptin, for treating lipodystrophy (Araujo-Vilar and Santini, 2019) because of its proven efficacy in treating leptin deficiency disease compared to its lack of efficacy in treating common obesity with hyperleptinemia.